⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNAZ News
TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
prnewswire.com
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
prnewswire.com
RNAZ
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
accessnewswire.com
RNAZ
DWTX
Form 8-K
sec.gov
RNAZ
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
prnewswire.com
RNAZ
Form 8-K
sec.gov
RNAZ
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
prnewswire.com
RNAZ
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
prnewswire.com
RNAZ
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
prnewswire.com
RNAZ